Your browser doesn't support javascript.
loading
In-hospital initiation of PCSK9 inhibitors in ACS: pros and cons.
Krychtiuk, Konstantin A; Claeys, Marc J; Gencer, Baris; Mach, François.
Affiliation
  • Krychtiuk KA; Division of Cardiology, Department of Internal Medicine II, Medical University of Vienna, Vienna, Austria.
  • Claeys MJ; Duke Clinical Research Institute, Durham, NC, USA.
  • Gencer B; Department of Cardiology, Antwerp University Hospital, Edegem, Belgium.
  • Mach F; Department of Cardiology, Geneva University Hospital (HUG), University of Geneva, Geneva, Switzerland.
EuroIntervention ; 19(4): e283-e285, 2023 07 17.
Article in En | MEDLINE | ID: mdl-37458121
Subject(s)
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hydroxymethylglutaryl-CoA Reductase Inhibitors / PCSK9 Inhibitors Limits: Humans Language: En Journal: EuroIntervention Year: 2023 Document type: Article
Fulltext
Print
XML
PubMed Links
Search on Google

Full text: 1 Collection: 01-internacional Database: MEDLINE Main subject: Hydroxymethylglutaryl-CoA Reductase Inhibitors / PCSK9 Inhibitors Limits: Humans Language: En Journal: EuroIntervention Year: 2023 Document type: Article